StockNASDAQ · US · USDHealthcare · Diagnostics & Research
$NEO
NEOGENOMICS INC
NeoGenomics provides oncology diagnostic testing and consultative services, including laboratory testing and professional interpretation by physicians and molecular experts specializing in pathology and oncology. It operates a network of cancer-focused laboratories in the United States and the United Kingdom and reports one operating segment. Its clients include community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, clinicians, and pharmaceutical companies. Its services include cytogenetics, FISH, flow cytometry, immunohistochemistry, molecular residual disease testing, molecular and next-generation sequencing tests, and pathologist consultations. NeoGenomics also supports pharmaceutical research studies and clinical trials with laboratory testing, biomarker analysis, and related scientific services, and licenses de-identified oncology data to pharmaceutical and biotech customers. It earns money from clinical cancer testing, interpretation and consultative services, research support, validation laboratory services, and oncology data solutions. NeoGenomics is headquartered in Fort Myers, Florida.
NeoGenomics reported Q3 growth driven by advanced clinical testing, improved product mix, and operational efficiency. NGS revenue grew 29% and volume 17%, while RaDaR ST MRD test adoption gained traction. Adjusted gross margin expanded over 300 basis points year-over-year. Leadership transition planned with strategic continuity. Nonclinical business remains a headwind. Future growth expected from NGS, MRD tests, and margin expansion.
TD Cowen reaffirmed its Buy rating for NeoGenomics and increased its price target to $23 from $19, citing a 27.8% upside from the last close. Recent analyst price targets for the company range from $20 to $28.
NeoGenomics Inc. (NASDAQ:NEO) reported Q3 2026 revenue of $209M (up 11% YoY) and adjusted EBITDA of $19M (up 53% YoY), raising full-year guidance. Clinical revenue grew 13% YoY, driven by NGS tests. The company announced leadership changes and secured MolDX reimbursement for IO monitoring. Shares closed at $17.99, up 4.17%.
via TradingView
NEO sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NEO (NEOGENOMICS INC). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent NEO coverage spans earnings and financial news.
What's driving NEO
NeoGenomics shows strong growth and margin improvement, but the piece is a post‑earnings recap without new guidance.
AlphAI scores every news story that mentions NEO with an AI model for sentiment and relevance, and aggregates insider trades from NEOGENOMICS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
NeoGenomics reported Q3 growth driven by advanced clinical testing, improved product mix, and operational efficiency. NGS revenue grew 29% and volume 17%, while RaDaR ST MRD test adoption gained traction. Adjusted gross margin expanded over 300 basis points year-over-year. Leadership transition planned with strategic continuity. Nonclinical business remains a headwind. Future growth expected from NGS, MRD tests, and margin expansion.
TD Cowen reaffirmed its Buy rating for NeoGenomics and increased its price target to $23 from $19, citing a 27.8% upside from the last close. Recent analyst price targets for the company range from $20 to $28.
NeoGenomics Inc. (NASDAQ:NEO) reported Q3 2026 revenue of $209M (up 11% YoY) and adjusted EBITDA of $19M (up 53% YoY), raising full-year guidance. Clinical revenue grew 13% YoY, driven by NGS tests. The company announced leadership changes and secured MolDX reimbursement for IO monitoring. Shares closed at $17.99, up 4.17%.
NeoGenomics reported Q3 2026 revenue of $209.3M, beating estimates by 1.1%. Adjusted EPS was $0.07, a 26.2% beat. Adjusted EBITDA was $18.67M, an 17.9% beat. The company raised full-year revenue guidance to $808M and adjusted EPS to $0.22, with EBITDA guidance at $60M, above estimates.
NEOGENOMICS INC (NEO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NeoGenomics Reports Third Quarter 2026 Results Total revenue increased 11% YoY to $209 million Clinical services revenue grew 13%, with NGS revenue growth of 29% Company raises full-year 2026 revenue and adjusted EBITDA guidance Fort Myers, Florida (October 28, 2026)
NeoGenomics reported a 72% reduction in its quarterly loss to $8 million, with total revenue increasing. Clinical services revenue grew, and the company raised its full-year 2026 revenue and adjusted EBITDA guidance. CEO Tony Zook attributed the results to the right strategy and team. The company will discuss the results on a conference call.
Neo Performance Materials (NEO) was invited to prepare a grant agreement for up to €126M from the EU Innovation Fund, supporting its €400M Estonia rare earth magnet project. Final agreement and FID are pending.
Labcorp and other testing & diagnostics services stocks reported Q2 earnings. RadNet (RDNT) reported $622.7M revenue, up 25% YoY, but stock is down 8%. NeoGenomics (NEO) reported $201.7M revenue, up 11.2%, and stock is up 26.4%. Quest (DGX) reported $3.04B revenue, up 10.2%, and stock is up 11.3%. Guardant Health (GH) reported $335M revenue, up 44.3%, and stock is up 6%.
NeoGenomics expands its digital pathology operations by adopting Indica Labs' HALO AP® platform. The cloud-based system aims to streamline workflows, reduce costs, and enhance AI integration for cancer diagnostics. NeoGenomics expects this to support future AI collaborations and clinical trials, positioning it for advancements in oncology care. The company has a long-standing relationship with Indica Labs and views this as a strategic step in integrated oncology diagnostics.
Argus lowered its target price for NeoGenomics Inc. (NEO) to $17.00. The company offers oncology diagnostic testing and consultative services. NEO provides technical lab services and professional interpretation of test results by licensed physicians or molecular experts in pathology and oncology.
